Palisade Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.06M Buy
44,085
+3,250
+8% +$85K 0.1% 118
2026
Q1
$1.15M Sell
40,835
-1,126
-3% -$30K 0.12% 110
2025
Q4
$1.04M Sell
41,961
-1,305
-3% -$32.9K 0.1% 115
2025
Q3
$1.1M Sell
43,266
-520
-1% -$12.8K 0.1% 112
2025
Q2
$1.06M Sell
43,786
-4,200
-9% -$97.9K 0.11% 113
2025
Q1
$1.22M Sell
47,986
-2,327
-5% -$60.9K 0.12% 107
2024
Q4
$1.33M Buy
50,313
+78
+0.2% +$2.12K 0.14% 102
2024
Q3
$1.45M Buy
50,235
+1,295
+3% +$37.8K 0.14% 101
2024
Q2
$1.37M Buy
48,940
+5
+0% +$138 0.14% 106
2024
Q1
$1.36M Buy
48,935
+1,700
+4% +$47.2K 0.13% 110
2023
Q4
$1.36M Sell
47,235
-4,095
-8% -$124K 0.15% 101
2023
Q3
$1.7M Buy
51,330
+1,475
+3% +$52.2K 0.21% 88
2023
Q2
$1.83M Buy
49,855
+300
+0.6% +$11.7K 0.21% 87
2023
Q1
$2.02M Buy
49,555
+840
+2% +$36.3K 0.25% 85
2022
Q4
$2.5M Buy
48,715
+425
+0.9% +$20.4K 0.29% 77
2022
Q3
$2.11M Sell
48,290
-510
-1% -$24.8K 0.29% 77
2022
Q2
$2.56M Buy
48,800
+1,340
+3% +$68.3K 0.33% 72
2022
Q1
$2.46M Buy
47,460
+3,600
+8% +$187K 0.28% 76
2021
Q4
$2.59M Sell
43,860
-1,950
-4% -$96.6K 0.29% 74
2021
Q3
$1.97M Buy
45,810
+730
+2% +$32.3K 0.24% 80
2021
Q2
$1.76M Buy
45,080
+1,494
+3% +$58.1K 0.21% 84
2021
Q1
$1.58M Sell
43,586
-22,371
-34% -$794K 0.2% 88
2020
Q4
$2.43M Sell
65,957
-2,481
-4% -$91K 0.33% 72
2020
Q3
$2.38M Hold
68,438
0.36% 71
2020
Q2
$2.12M Buy
68,438
+3,030
+5% +$103K 0.34% 71
2020
Q1
$2.03M Buy
65,408
+2,283
+4% +$77.8K 0.37% 68
2019
Q4
$2.35M Buy
63,125
+2,480
+4% +$88.3K 0.34% 71
2019
Q3
$2.07M Buy
60,645
+1,324
+2% +$48.1K 0.32% 72
2019
Q2
$2.44M Buy
59,321
+186
+0.3% +$7.39K 0.38% 68
2019
Q1
$2.38M Buy
59,135
+412
+0.7% +$16.5K 0.38% 69
2018
Q4
$2.43M Sell
58,723
-26
-0% -$1.08K 0.36% 63
2018
Q3
$2.46M Buy
58,749
+1,007
+2% +$38.8K 0.32% 67
2018
Q2
$1.99M Buy
57,742
+1,317
+2% +$45K 0.29% 69
2018
Q1
$1.9M Hold
56,425
0.29% 71
2017
Q4
$1.94M Sell
56,425
-105
-0.2% -$3.58K 0.31% 71
2017
Q3
$1.92M Buy
56,530
+290
+0.5% +$9.32K 0.35% 63
2017
Q2
$1.79M Hold
56,240
0.35% 64
2017
Q1
$1.82M Buy
56,240
+3,857
+7% +$122K 0.34% 57
2016
Q4
$1.61M Sell
52,383
-474
-0.9% -$14.5K 0.31% 64
2016
Q3
$1.7M Hold
52,857
0.32% 64
2016
Q2
$1.77M Hold
52,857
0.33% 64
2016
Q1
$1.49M Buy
52,857
+316
+0.6% +$9.03K 0.29% 70
2015
Q4
$1.61M Sell
52,541
-316
-0.6% -$9.94K 0.34% 61
2015
Q3
$1.57M Hold
52,857
0.35% 66
2015
Q2
$1.68M Sell
52,857
-456
-0.9% -$14.9K 0.33% 67
2015
Q1
$1.76M Buy
53,313
+590
+1% +$18.8K 0.35% 64
2014
Q4
$1.56M Buy
52,723
+253
+0.5% +$7.25K 0.31% 66
2014
Q3
$1.47M Buy
52,470
+882
+2% +$24.8K 0.3% 68
2014
Q2
$1.45M Buy
51,588
+33
+0.1% +$941 0.31% 67
2014
Q1
$1.57M Hold
51,555
0.34% 60
2013
Q4
$1.5M Buy
51,555
+527
+1% +$15.3K 0.34% 63
2013
Q3
$1.39M Sell
51,028
-2,393
-4% -$65.1K 0.35% 62
2013
Q2
$1.42M Buy
+53,421
New +$1.48M 0.36% 62

Other funds holding PFE

Palisade Asset Management's PFE Position: Q2 2026 in Review

Palisade Asset Management increased its Pfizer (PFE) stake by 8% in Q2 2026, buying an estimated $85K and bringing the position to 44,085 shares worth $1.06M. The position accounts for 0.1% of the portfolio, ranked #118.

Palisade Asset Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.59M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Palisade Asset Management held 44,085 shares of Pfizer worth $1.06M as of Q2 2026.
  • Palisade Asset Management bought 3,250 Pfizer shares in Q2 2026, an estimated $85K.
  • Pfizer made up 0.1% of Palisade Asset Management's portfolio in Q2 2026, its #118 holding.
  • Palisade Asset Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Palisade Asset Management's Pfizer position peaked at $2.59M in Q4 2021.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Palisade Asset Management's 13F filing for Q2 2026, filed 20 Jul 2026.